Rutaecarpine Induces the Differentiation of Triple-negative Breast Cancer Cells Through Inhibiting Fumarate Hydratase

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Aug 17

PMID 37592347

Authors

Jie Lei

Yujia Pan

Rui Gao

Bin He

Zifeng Wang

Xinxing Lei

Zijian Zhang

Na Yang

Min Yan

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC) is one of the most aggressive human cancers and has poor prognosis. Approximately 80% of TNBC cases belong to the molecular basal-like subtype, which can be exploited therapeutically by inducing differentiation. However, the strategies for inducing the differentiation of TNBC remain underexplored.

Methods: A three-dimensional (3D) morphological screening model based on a natural compound library was used to identify possible candidate compounds that can induce TNBC cell differentiation. The efficacy of rutaecarpine was verified using assays: RT-qPCR, RNA-seq, flow cytometry, immunofluorescence, SCENITH and label-free LC-MS/MS. The direct targets of rutaecarpine were identified through drug affinity responsive target stability (DARTS) assay. A xenograft mice model was also constructed to confirm the effect of rutaecarpine in vivo.

Results: We identified that rutaecarpine, an indolopyridoquinazolinone, induces luminal differentiation of basal TNBC cells in both 3D spheroids and in vivo mice models. Mechanistically, rutaecarpine treatment leads to global metabolic stress and elevated ROS in 3D cultured TNBC cells. Moreover, NAC, a scavenger of ROS, impedes rutaecarpine-induced differentiation of TNBC cells in 3D culture. Finally, we identified fumarate hydratase (FH) as the direct interacting target of rutaecarpine. The inhibition of FH and the knockdown of FH consistently induced the differentiation of TNBC cells in 3D culture.

Conclusions: Our results provide a platform for differentiation therapy drug discovery using 3D culture models and identify rutaecarpine as a potential compound for TNBC treatment.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Liu X, Bai F, Wang Y, Wang C, Chan H, Zheng C . Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis. Cell Death Dis. 2023; 14(6):370. PMC: 10290069. DOI: 10.1038/s41419-023-05888-9. View

Ma Y, Lu Y, Wu Q, Lou Y, Yang M, Xu J . Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia. J Hematol Oncol. 2022; 15(1):148. PMC: 9578225. DOI: 10.1186/s13045-022-01368-3. View

Sabharwal S, Schumacker P . Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat Rev Cancer. 2014; 14(11):709-21. PMC: 4657553. DOI: 10.1038/nrc3803. View

Yin L, Duan J, Bian X, Yu S . Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1):61. PMC: 7285581. DOI: 10.1186/s13058-020-01296-5. View

Khasraghi L, Nouri M, Vazirzadeh M, Hashemipour N, Talebi M, Zarch F . MicroRNA-206 in human cancer: Mechanistic and clinical perspectives. Cell Signal. 2022; 101():110525. DOI: 10.1016/j.cellsig.2022.110525. View

Zhang Y, Yang Y, Yang X . Blood-brain barrier permeability and neuroprotective effects of three main alkaloids from the fruits of Euodia rutaecarpa with MDCK-pHaMDR cell monolayer and PC12 cell line. Biomed Pharmacother. 2017; 98:82-87. DOI: 10.1016/j.biopha.2017.12.017. View

Jiang L, Shestov A, Swain P, Yang C, Parker S, Wang Q . Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 2016; 532(7598):255-8. PMC: 4860952. DOI: 10.1038/nature17393. View

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

10.

Chou J, Lin J, Brenot A, Kim J, Provot S, Werb Z . GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013; 15(2):201-13. PMC: 3660859. DOI: 10.1038/ncb2672. View

11.

Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View

12.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

13.

Chin R, Fu X, Pai M, Vergnes L, Hwang H, Deng G . The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014; 510(7505):397-401. PMC: 4263271. DOI: 10.1038/nature13264. View

14.

Yan M, Liu Q . Differentiation therapy: a promising strategy for cancer treatment. Chin J Cancer. 2016; 35:3. PMC: 4704415. DOI: 10.1186/s40880-015-0059-x. View

15.

Wu J, Huang T, Hsieh Y, Wang Y, Yen C, Lee G . Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor. Mol Cell. 2019; 77(2):213-227.e5. DOI: 10.1016/j.molcel.2019.10.023. View

16.

Faramin Lashkarian M, Hashemipour N, Niaraki N, Soghala S, Moradi A, Sarhangi S . MicroRNA-122 in human cancers: from mechanistic to clinical perspectives. Cancer Cell Int. 2023; 23(1):29. PMC: 9940444. DOI: 10.1186/s12935-023-02868-z. View

17.

Byun W, Bae E, Kim W, Lee S . Antitumor Activity of Rutaecarpine in Human Colorectal Cancer Cells by Suppression of Wnt/β-Catenin Signaling. J Nat Prod. 2022; 85(5):1407-1418. DOI: 10.1021/acs.jnatprod.2c00224. View

18.

Sahraeian S, Mohiyuddin M, Sebra R, Tilgner H, Afshar P, Au K . Gaining comprehensive biological insight into the transcriptome by performing a broad-spectrum RNA-seq analysis. Nat Commun. 2017; 8(1):59. PMC: 5498581. DOI: 10.1038/s41467-017-00050-4. View

19.

Newman D, Cragg G . Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020; 83(3):770-803. DOI: 10.1021/acs.jnatprod.9b01285. View

20.

Arif T, Amsalem Z, Shoshan-Barmatz V . Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells. Mol Ther Nucleic Acids. 2019; 17:24-37. PMC: 6562189. DOI: 10.1016/j.omtn.2019.05.003. View